| HOME >> MEDICINE >> TECHNOLOGY |
NEW YORK, Dec. 4 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced approximately $2.5 million in total funding for five clinical research studies under its 2007 Clinical Discovery Program. In keeping with the Foundation's focus on accelerating scientific solutions that can have a tangible effect on patients' lives, this annual initiative funds clinical research projects with strong potential to yield new treatments for people living with PD.
"The Clinical Discovery Program is characteristic of the MJFF approach to translation: it vigorously aims to accelerate progress and directly benefit patients," said Katie Hood, interim chief executive officer of The Michael J. Fox Foundation for Parkinson's Research. "Many potentially groundbreaking clinical ideas lack funding to move forward and gain traction. Under Clinical Discovery the Foundation partners with the teams that can execute the clinical research critical to moving good ideas one step closer to people with Parkinson's disease."
The Foundation launched the Clinical Discovery Program in 2004 and has awarded approximately $10 million for 17 projects under the initiative to date. Each of this year's studies will focus specifically on improving the patient's quality of life. Funded projects will address common and debilitating aspects of PD such as depression, dyskinesia (the uncontrollable movements that are a side effect of long-term levodopa treatment), sleep disorders and excessive salivation.
"The Michael J. Fox Foundation is committed to driving clinical
research to improve the lives of the nearly five million people living with
Parkinson's," said Irene Richard, MD, who was appointed today as the senior
medical advisor at the Foundation. "The Clinical Discovery Program is a
cornerstone of the Foundation's emphasis on speeding promising ideas toward
the clinic with the goal of getting them into patients' hands that much
faster."
'/>"/>
| SOURCE Michael J. Fox Foundation Copyright©2007 PR Newswire. All rights reserved |